These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 36424271)

  • 1. Current approaches for the diagnosis and management of immune thrombocytopenia.
    Gafter-Gvili A
    Eur J Intern Med; 2023 Feb; 108():18-24. PubMed ID: 36424271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnostic approach and treatment of immune thrombocytopenia in adults].
    Kolonić SO; Patekar MB; Milunović V
    Acta Med Croatica; 2013 Mar; 67(1):3-11. PubMed ID: 24279250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune thrombocytopenia.
    Bussel J; Cooper N; Boccia R; Zaja F; Newland A
    Expert Rev Hematol; 2021 Nov; 14(11):1013-1025. PubMed ID: 34720027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Thrombocytopenia in Children: Consensus and Controversies.
    Singh G; Bansal D; Wright NAM
    Indian J Pediatr; 2020 Feb; 87(2):150-157. PubMed ID: 31927692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary management of primary immune thrombocytopenia in adults.
    Lakshmanan S; Cuker A
    J Thromb Haemost; 2012 Oct; 10(10):1988-98. PubMed ID: 22863415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombopoietin Receptor Agonists and Other Second-Line Therapies for Immune Thrombocytopenia: A Narrative Review With a Focus on Drug Access in Canada.
    Britto J; Holbrook A; Sun H; Cserti-Gazdewich C; Prokopchuk-Gauk O; Hsia C; Khamisa K; Yenson PR; Sholzberg M; Olney HJ; Shivakumar S; Jones D; Merkeley H; Costello J; Jamula E; Arnold DM
    Clin Invest Med; 2024 Mar; 47(1):13-22. PubMed ID: 38546381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of ITP].
    Yokoyama K
    Rinsho Ketsueki; 2021; 62(8):1229-1235. PubMed ID: 34497211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study.
    Podstawka J; Wall E; Bolster L; Patterson JM; Goodyear MD; Rydz N; Sun HL
    Thromb Res; 2022 Dec; 220():5-11. PubMed ID: 36257098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current options for the treatment of idiopathic thrombocytopenic purpura.
    Arnold DM; Kelton JG
    Semin Hematol; 2007 Oct; 44(4 Suppl 5):S12-23. PubMed ID: 18096468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequence of treatments for adults with primary immune thrombocytopenia.
    George JN
    Am J Hematol; 2012 May; 87 Suppl 1():S12-5. PubMed ID: 22389032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment.
    Ghanima W; Gernsheimer T; Kuter DJ
    Blood; 2021 May; 137(20):2736-2744. PubMed ID: 33827138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia.
    Lozano ML; Godeau B; Grainger J; Matzdorff A; Rodeghiero F; Hippenmeyer J; Kuter DJ
    Expert Rev Hematol; 2020 Dec; 13(12):1319-1332. PubMed ID: 33249935
    [No Abstract]   [Full Text] [Related]  

  • 14. [Differential diagnosis and therapy of immune thrombocytopenia].
    Giagounidis A
    Dtsch Med Wochenschr; 2024 Aug; 149(15):895-903. PubMed ID: 39013410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How we treat primary immune thrombocytopenia in adults.
    Liu XG; Hou Y; Hou M
    J Hematol Oncol; 2023 Jan; 16(1):4. PubMed ID: 36658588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?
    Lv Y; Shi H; Liu H; Zhou L
    Front Immunol; 2022; 13():953716. PubMed ID: 36003388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat.
    Rodeghiero F
    Eur J Haematol Suppl; 2008 Feb; (69):19-26. PubMed ID: 18211569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults.
    Kikuchi K; Miyakawa Y; Ikeda S; Sato Y; Takebayashi T
    BMC Health Serv Res; 2015 Jan; 15():2. PubMed ID: 25609557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positioning new treatments in the management of immune thrombocytopenia.
    Arnold DM
    Pediatr Blood Cancer; 2013; 60 Suppl 1(Suppl 1):S19-22. PubMed ID: 23109488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.
    Vianelli N; Auteri G; Buccisano F; Carrai V; Baldacci E; Clissa C; Bartoletti D; Giuffrida G; Magro D; Rivolti E; Esposito D; Podda GM; Palandri F
    Ann Hematol; 2022 May; 101(5):963-978. PubMed ID: 35201417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.